Company Profile
Celldex Therapeutics Stock Price, News & Analysis
- Ticker:
- CLDX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
41.56 USD (+1.22%)
Close
Last updated: August 6, 2026
2.27B USD
Market cap
Why the stock is moving
The latest monitored company update is “Celldex Reports Second Quarter Financial Results and Provides Corporate Update.” The corresponding closing-price reaction is not yet available.
Company overview
Mast Cell-Targeted Immunology Company
Celldex Therapeutics is developing barzolvolimab, a KIT-targeting antibody for mast cell-driven diseases. Because KIT signaling is central to mast cell survival and function, the therapy is intended to provide deeper disease modification than symptom-focused treatment alone.
Barzolvolimab in CSU
Long-term Phase 2 data presented at EAACI showed rapid, substantial, and durable improvement in angioedema among patients with chronic spontaneous urticaria who remained symptomatic despite antihistamines. Some patients remained angioedema-free at Week 76, seven months after treatment ended.
Late-Stage Registration Strategy
CSU is the lead registrational indication for barzolvolimab, supported by two fully enrolled Phase 3 studies. A successful program would establish the first commercial use of the asset and provide clinical validation for broader KIT-mediated mast cell depletion.
Franchise Expansion Beyond CSU
Cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis provide follow-on opportunities using the same KIT-targeting mechanism. This creates the potential for a multi-indication mast cell disease franchise rather than a single-product, single-market program.
Multi-Indication Development
Barzolvolimab is being advanced in CSU, cold urticaria and symptomatic dermographism, prurigo nodularis, and atopic dermatitis, supporting its potential as a single-mechanism platform across multiple mast cell-related diseases.
Future catalysts
Topline data from two fully enrolled Phase 3 studies of barzolvolimab in CSU are expected in the fourth quarter of 2026.
Celldex plans to use the CSU Phase 3 results to support a BLA submission in 2027.
Barzolvolimab is also advancing in Phase 3 studies for ColdU and symptomatic dermographism and in Phase 2 studies for prurigo nodularis and atopic dermatitis, with future readouts potentially expanding the franchise.
Recent news
- 01
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Source: Celldex Therapeutics
- 02
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Source: Celldex Therapeutics
- 03
Celldex Announces Planned Transition of Chief Financial Officer
Source: Celldex Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Celldex Therapeutics (CLDX)?
Celldex Therapeutics (CLDX) most recently closed at 41.56 USD, a +1.22% move versus the previous session.
What is the market cap of Celldex Therapeutics (CLDX)?
Celldex Therapeutics currently has a market capitalization of 2.27B USD on BioPharmSignal.
What does Celldex Therapeutics do?
Mast Cell-Targeted Immunology Company Celldex Therapeutics is developing barzolvolimab, a KIT-targeting antibody for mast cell-driven diseases. Because KIT signaling is central to mast cell survival and function, the therapy is intended to provide deeper disease modification than symptom-focused treatment alone. Barzolvolimab in CSU Long-term Phase 2 data...
On which exchange is CLDX stock listed?
Celldex Therapeutics (CLDX) is associated with NASDAQ, United States, Biopharma.
What is barzolvolimab?
Topline data from two fully enrolled Phase 3 studies of barzolvolimab in CSU are expected in the fourth quarter of 2026.
Which conditions is Celldex Therapeutics targeting with barzolvolimab?
Celldex Therapeutics is associated with immunology based on its company overview and current catalyst commentary.
How does Celldex Therapeutics describe recent progress with barzolvolimab?
Topline data from two fully enrolled Phase 3 studies of barzolvolimab in CSU are expected in the fourth quarter of 2026.
What is Mast?
Mast Cell-Targeted Immunology Company Celldex Therapeutics is developing barzolvolimab, a KIT-targeting antibody for mast cell-driven diseases.